RESEARCH TRIANGLE PARK, NC--(Marketwire - March 03, 2008) - Tranzyme Pharma today announced that it has commenced dosing in a Phase I study of TZP-102, the Company's second generation, orally-administered ghrelin agonist. TZP-102 is a potent prokinetic agent that Tranzyme is initially developing for the treatment of mild-to-moderate gastroparesis, with other chronic gastrointestinal (GI) motility disorders to follow.